We establish a novel distance (cut-off) score based on ESPL1, PTTG1 and PTTG1IP gene expression levels that can serve as predictors of TKI non-response in about 10% of analyzed non-responding patients and may have potential benefit for the risk stratification of CML patients. This evidence concerns the gene PTTG1 and chronic myelogenous leukemia, BCR-ABL1 positive.